Zentek Engages IMPAQ Capital Inc. to Broaden Investor Awareness Across North America

This is a routine IR contract with technical updates, not a catalyst for investors.

What the company is saying

Zentek Ltd. is announcing the engagement of IMPAQ Capital Inc. to provide investor relations services, emphasizing its commitment to professional outreach across North America. The company wants investors to believe that this partnership will enhance market visibility and attract investment professionals, supporting Zentek’s growth ambitions. The announcement highlights the technical achievement of purifying Albany graphite to 99.9992% at bench scale, positioning it as nuclear-grade and suitable for critical supply chains. It also claims that ZenGUARD™, Zentek’s graphene coating platform, is already generating commercial revenue, though no figures are provided. The company frames the Albany Graphite Project as a potential domestic source for nuclear, battery, and defense sectors, projecting a NI 43-101 Preliminary Economic Assessment (PEA) for summer 2026. The release is careful to note that IMPAQ is being paid in cash only, with no securities or options issued, and that neither IMPAQ nor its insiders hold Zentek shares, aiming to reassure investors about independence and alignment. The tone is confident and positive, focusing on technical milestones and future potential, but avoids specifics on financial performance or operational progress. Notable individuals named include Mohammed (Moe) Jiwan, Zentek’s CEO, and Peter Wood, VP Development of AGC, but their roles are referenced only in passing, with no direct involvement in the IR engagement or new strategic moves. Overall, the narrative is designed to project progress and professionalism, but it is light on hard evidence of commercial traction or near-term value creation.

What the data suggests

The only concrete financial data disclosed is the monthly cash fee of C$13,500 (plus taxes) to IMPAQ Capital Inc. for a six-month initial term, with automatic three-month renewals. There are no revenue, profit, cash flow, or balance sheet figures provided for Zentek or its projects. The technical data confirms Albany graphite has achieved 99.9992% purity and a boron concentration of 2.60 ppm at bench scale, which aligns with nuclear-grade benchmarks, but this is a laboratory result, not a commercial or production milestone. The claim that ZenGUARD™ is generating commercial revenue is unsubstantiated, as no actual revenue numbers or growth rates are disclosed. There is no evidence of project advancement beyond bench-scale testing, nor are there details on customer contracts, production volumes, or supply agreements. The financial trajectory of the company cannot be assessed from this announcement, as there are no period-over-period comparisons or operational metrics. The quality of disclosure is adequate for the IR contract and technical assay, but wholly insufficient for evaluating business performance or investment merit. An independent analyst would conclude that, based on the numbers alone, there is no new information to support a change in investment thesis or valuation.

Analysis

The announcement is primarily factual, disclosing the engagement of IMPAQ Capital Inc. for investor relations services, with clear terms and compensation. Technical milestones, such as bench-scale purification of Albany graphite and its boron concentration, are reported as realised facts. However, forward-looking statements about the Albany Graphite Project's potential as a domestic source for critical supply chains and the upcoming NI 43-101 PEA are aspirational and lack supporting financial or operational data. The mention of ZenGUARD™ generating commercial revenue is not substantiated with figures, limiting the ability to assess its materiality. No large capital outlay or immediate earnings impact is disclosed, and the only financial detail is the IR service fee. The overall tone is positive but proportionate to the evidence, with minimal narrative inflation.

Risk flags

• ●The majority of claims in this announcement are forward-looking, such as the Albany project’s potential as a domestic source for critical-grade graphite and the upcoming PEA. This matters because forward-looking statements are inherently uncertain and often fail to materialize, especially in resource development.
• ●There is a lack of financial disclosure regarding Zentek’s core business operations. No revenue, profit, cash flow, or balance sheet data is provided, making it impossible for investors to assess financial health or sustainability.
• ●The technical achievement of 99.9992% purity for Albany graphite is at bench scale only. Bench-scale results do not guarantee scalability, economic viability, or regulatory approval for commercial production, which are critical for investment returns.
• ●The claim that ZenGUARD™ is generating commercial revenue is unsupported by any figures or customer data. This raises concerns about the materiality of this revenue and whether it is significant enough to impact valuation.
• ●The IR engagement with IMPAQ Capital Inc. is a routine service contract, not a strategic partnership or capital infusion. While it may improve investor outreach, it does not directly advance project development or financial performance.
• ●Execution risk is high for the Albany project, as moving from technical validation to commercial production typically requires substantial capital, regulatory approvals, and market demand, none of which are addressed in this announcement.
• ●The timeline to value realization is long, with the next major milestone (the PEA) not expected until summer 2026. Investors face the risk of capital being tied up for years before any potential payoff, with no interim financial or operational milestones disclosed.
• ●Geographic references to North America, Ontario, Quebec, Canada, and the United States are broad and do not clarify where actual operations, permitting, or market entry will occur, adding uncertainty about jurisdictional and regulatory risks.

Bottom line

For investors, this announcement is primarily a disclosure of a standard investor relations contract and a reiteration of technical progress at the bench scale for the Albany graphite project. There is no new information about Zentek’s financial performance, commercial traction, or near-term catalysts that would justify a change in investment stance. The narrative is credible in its factual reporting of the IR engagement and technical assay, but the claims of commercial revenue and project advancement are not substantiated with data. No notable institutional figures are participating in a way that signals external validation or imminent capital inflow. To materially change this assessment, Zentek would need to disclose actual revenue figures for ZenGUARD™, binding offtake agreements, production milestones, or detailed financial statements. Investors should watch for the completion and results of the NI 43-101 PEA in summer 2026, as well as any concrete evidence of commercial sales or project financing. At present, this announcement is not actionable from an investment perspective; it is best viewed as a routine update to be monitored rather than a signal to buy or sell. The single most important takeaway is that, despite positive technical progress, there is no new financial or operational evidence to support a change in investment outlook.

Announcement summary

(TSXV:ZEN) Zentek Ltd. has engaged IMPAQ Capital Inc., an independent, arm's-length service provider, to deliver investor relations services for a monthly cash fee of C$13,500, plus applicable taxes. The agreement is for an initial term of six months commencing July 20, 2026, and will automatically renew for successive three-month periods unless terminated by the Company. IMPAQ will conduct outreach to investment professionals across North America and provide regular activity reports to Zentek. Albany, Zentek's principal critical minerals asset, has been independently purified to 99.9992% purity at bench scale, with an equivalent boron concentration of 2.60 ppm, consistent with published benchmarks for nuclear-grade graphite. ZenGUARD™, Zentek's patented graphene coating platform, is already generating commercial revenue. The company projects a NI 43-101 Preliminary Economic Assessment for Albany to be completed in summer 2026. No securities are being issued to IMPAQ in connection with the engagement, and neither IMPAQ nor its insiders holds any shares or options to purchase shares in Zentek.

Disagree with this article?